zonisamide has been researched along with Parkinson Disease in 51 studies
Zonisamide: A benzisoxazole and sulfonamide derivative that acts as a CALCIUM CHANNEL blocker. It is used primarily as an adjunctive antiepileptic agent for the treatment of PARTIAL SEIZURES, with or without secondary generalization.
zonisamide : A 1,2-benzoxazole compound having a sulfamoylmethyl substituent at the 3-position.
Parkinson Disease: A progressive, degenerative neurologic disease characterized by a TREMOR that is maximal at rest, retropulsion (i.e. a tendency to fall backwards), rigidity, stooped posture, slowness of voluntary movements, and a masklike facial expression. Pathologic features include loss of melanin containing neurons in the substantia nigra and other pigmented nuclei of the brainstem. LEWY BODIES are present in the substantia nigra and locus coeruleus but may also be found in a related condition (LEWY BODY DISEASE, DIFFUSE) characterized by dementia in combination with varying degrees of parkinsonism. (Adams et al., Principles of Neurology, 6th ed, p1059, pp1067-75)
| Excerpt | Relevance | Reference |
|---|---|---|
| "Zonisamide at a dose of 25 mg per day did not improve tremor in tremor-dominant PD patients, however, a positive trend was seen as compared to Placebo in the UPDRS tremor score." | 9.51 | Zonisamide add-on in tremor-dominant Parkinson's disease- A randomized controlled clinical trial. ( Bhat, P; Elavarasi, A; Goyal, V; Pandit, AK; Pillai, KS; Prasad, K; Radhakrishnan, DM; Rajan, R; Singh, MB; Srivastava, AK; Srivastava, MP; Vishnu, VY, 2022) |
| "To evaluate the efficacy, safety and tolerability of daily doses of 25, 50, and 100 mg of zonisamide (ZNS) administered as adjunctive treatment in patients with Parkinson disease (PD)." | 9.12 | Zonisamide improves motor function in Parkinson disease: a randomized, double-blind study. ( Hasegawa, K; Kanazawa, I; Murata, M, 2007) |
| "This study examined whether zonisamide (ZNS) cotreatment delays dopamine transporter (DAT) reduction on SPECT in Parkinson disease (PD) patients." | 7.88 | Zonisamide cotreatment delays striatal dopamine transporter reduction in Parkinson disease: A retrospective, observational cohort study. ( Hirayama, T; Ikeda, K; Ishikawa, Y; Iwasaki, Y; Kano, O; Kawabe, K; Miura, K; Mizumura, N; Takazawa, T; Yanagihashi, M, 2018) |
| "Zonisamide is an antiepileptic drug used as adjunctive therapy for refractory partial seizures in adults." | 6.43 | Zonisamide: review of its use in epilepsy therapy. ( Zareba, G, 2005) |
| "Zonisamide at a dose of 25 mg per day did not improve tremor in tremor-dominant PD patients, however, a positive trend was seen as compared to Placebo in the UPDRS tremor score." | 5.51 | Zonisamide add-on in tremor-dominant Parkinson's disease- A randomized controlled clinical trial. ( Bhat, P; Elavarasi, A; Goyal, V; Pandit, AK; Pillai, KS; Prasad, K; Radhakrishnan, DM; Rajan, R; Singh, MB; Srivastava, AK; Srivastava, MP; Vishnu, VY, 2022) |
| "We aimed to evaluate the effect of zonisamide (ZNS) on motor symptoms and nonmotor symptoms such as depressive symptoms and sleep problems in Parkinson's disease (PD) patients with or without tremor." | 5.41 | Zonisamide effects on sleep problems and depressive symptoms in Parkinson's disease. ( Fujita, H; Funakoshi, K; Haruyama, Y; Hirata, K; Kadowaki, T; Matsubara, T; Suzuki, K; Watanabe, Y, 2021) |
| "Generally, resting tremor of patients with Parkinson's disease is not the main therapeutic target in this disease." | 5.32 | [Effect of zonisamide on resting tremor resistant to antiparkinsonian medication]. ( Kohmoto, J; Kondo, T; Miwa, H; Nakanishi, I, 2003) |
| "To evaluate the efficacy, safety and tolerability of daily doses of 25, 50, and 100 mg of zonisamide (ZNS) administered as adjunctive treatment in patients with Parkinson disease (PD)." | 5.12 | Zonisamide improves motor function in Parkinson disease: a randomized, double-blind study. ( Hasegawa, K; Kanazawa, I; Murata, M, 2007) |
| "We serendipitously found that zonisamide (ZNS), an antiepileptic agent, has beneficial effects on Parkinson disease." | 4.86 | [The discovery of an antiparkinsonian drug, zonisamide]. ( Murata, M, 2010) |
| "In this paper, I have discussed a modification in the current treatment strategy for Parkinson disease (PD) and the application of a new drug, zonisamide, for the treatment of PD." | 4.85 | [Pharmacologic treatment of Parkinson disease]. ( Murata, M, 2009) |
| "On the basis of six randomized controlled trials, zonisamide (ZNS) can be prescribed as add-on treatment in focal adulthood epilepsy in USA and Europe." | 4.85 | [Role of zonisamid in treating epilepsy, Parkinson disorders and other neurological diseases]. ( Janszky, J, 2009) |
| "In 11 patients with Parkinson's disease (PD) who were using levodopa and had hallucinations and/or delusions considered to be attributed to use of dopamine agonists (DAs), we reduced or discontinued DAs and added zonisamide, and we then evaluated the effects of this treatment on psychiatric and motor symptoms." | 4.02 | [Effects of switching from dopamine agonists to zonisamide on psychiatric and motor symptoms in patients with Parkinson's disease]. ( Abe, T; Maruyama, H, 2021) |
| "This study examined whether zonisamide (ZNS) cotreatment delays dopamine transporter (DAT) reduction on SPECT in Parkinson disease (PD) patients." | 3.88 | Zonisamide cotreatment delays striatal dopamine transporter reduction in Parkinson disease: A retrospective, observational cohort study. ( Hirayama, T; Ikeda, K; Ishikawa, Y; Iwasaki, Y; Kano, O; Kawabe, K; Miura, K; Mizumura, N; Takazawa, T; Yanagihashi, M, 2018) |
| "The anti-epileptic agent zonisamide (ZNS) has been shown to exert protective effects in neurotoxin-based mouse models of Parkinson disease." | 3.80 | Zonisamide attenuates α-synuclein neurotoxicity by an aggregation-independent mechanism in a rat model of familial Parkinson's disease. ( Arawaka, S; Fukushima, S; Kato, T; Koga, K; Koyama, S; Sasaki, A; Sato, H, 2014) |
| "Dyskinesia was evaluated using Unified Parkinson's Disease Rating Scale (UPDRS) part 4 items 32 (4-32; duration of dyskinesia) and 33 (4-33; disability of dyskinesia) score." | 3.01 | Zonisamide improves wearing off in Parkinson's disease without exacerbating dyskinesia: Post hoc analysis of phase 2 and phase 3 clinical trials. ( Maruyama, H; Matsumoto, Y; Nakamura, M; Tsuboi, Y, 2021) |
| " For safety outcomes, rasagiline was associated with a higher incidence of adverse events than placebo and safinamide." | 3.01 | Comparative efficacy and safety of monoamine oxidase type B inhibitors plus channel blockers and monoamine oxidase type B inhibitors as adjuvant therapy to levodopa in the treatment of Parkinson's disease: a network meta-analysis of randomized controlled ( Cai, G; Cai, H; Cui, Y; Feng, T; Lin, F; Su, D; Yan, R, 2023) |
| "Six zonisamide trials were included, five of which were conducted in Japan and one in India." | 3.01 | Efficacy and Safety of MAO-B Inhibitors Safinamide and Zonisamide in Parkinson's Disease: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. ( Abou-Setta, A; Aboulatta, L; Askin, N; Eltonsy, S; Haidar, L; Lavu, A; Peymani, P; Rabbani, R; Zarychanski, R, 2023) |
| " Adverse events reported in the RCTs will be considered in the final safety analysis." | 2.82 | Zonisamide's Efficacy and Safety on Parkinson's Disease and Dementia with Lewy Bodies: A Meta-Analysis and Systematic Review. ( Jiang, Z; Kong, L; Liu, H; Wang, Z; Xi, J; Yu, X, 2022) |
| "Zonisamide (ZNS) is a generally well tolerated anticonvulsant that has beneficial effects on Parkinson's disease (PD)." | 2.70 | Zonisamide has beneficial effects on Parkinson's disease patients. ( Horiuchi, E; Kanazawa, I; Murata, M, 2001) |
| "The prognosis of Parkinson's disease (PD) has been improved with developing anti-parkinsonian agents." | 2.44 | [Therapy of Parkinson's disease--up to date]. ( Murata, M, 2008) |
| "Zonisamide is an antiepileptic drug widely used to treat seizures worldwide." | 2.44 | Zonisamide for the treatment of Parkinson's disease. ( Miwa, H, 2007) |
| "Zonisamide is an antiepileptic drug used as adjunctive therapy for refractory partial seizures in adults." | 2.43 | Zonisamide: review of its use in epilepsy therapy. ( Zareba, G, 2005) |
| "Different dose-response meta-analysis models using linear, quadratic, and restricted cubic spline (RCS) functions were fitted." | 1.72 | Investigation of the Utility of Multivariate Meta-Analysis Methods in Estimating the Summary Dose Response Curve. ( Deepthy, MS; Harichandrakumar, KT; Karun, KM; Nair, NS, 2022) |
| "Zonisamide is a nondopaminergic antiparkinsonian drug that can improve "wearing-off" although response to the treatment varies between individuals." | 1.56 | Genome-wide association study identifies zonisamide responsive gene in Parkinson's disease patients. ( Ando-Kanagawa, Y; Cha, PC; Murata, M; Satake, W; Toda, T; Yamamoto, K, 2020) |
| "Among the therapeutic agents for Parkinson's disease (PD), there are important drugs that precede drug repositioning." | 1.51 | [Parkinson's Disease: amantadine, zonisamide, dabrafenib]. ( Okamoto, T, 2019) |
| "Patients with Parkinson's disease (PD) experience various symptoms, both from the disease progression itself and the medication." | 1.51 | Comparison of zonisamide with non-levodopa, anti-Parkinson's disease drugs in the incidence of Parkinson's disease-relevant symptoms. ( Iwaki, H; Iwasaki, K; Kawakami, K; Nomoto, M; Tagawa, M, 2019) |
| " The most widely used MAO-B inhibitor to maintain the bioavailability of dopamine in the brain of PD patients is L-deprenyl, despite of its potential side-effects." | 1.48 | Garcinol, an effective monoamine oxidase-B inhibitor for the treatment of Parkinson's disease. ( Bhattacharya, P; Borah, A; Chakrabarty, J; Dutta, A; Mazumder, MK; Paul, R; Phukan, BC, 2018) |
| "Zonisamide (ZNS) is an effective drug for not only motor symptoms but also non-motor symptoms in Parkinson's disease." | 1.46 | Zonisamide inhibits monoamine oxidase and enhances motor performance and social activity. ( Asano, T; Hikawa, R; Takahashi, R; Uemura, MT; Yamakado, H, 2017) |
| "Zonisamide has been reported to have protective effects on epilepsy and Parkinson׳s disease and to work via various mechanisms of action, such as inhibition of monoamine oxidase-B and enhancement of tyrosine hydroxylase." | 1.42 | Zonisamide suppresses endoplasmic reticulum stress-induced neuronal cell damage in vitro and in vivo. ( Hara, H; Hashizume, T; Ishisaka, M; Shimazawa, M; Tsujii, S, 2015) |
| "Zonisamide has multiple modes of action, and its effects on Parkinson's disease include activation of dopamine synthesis, inhibition of monoamine oxidase, inhibition of T-type calcium channels and inhibition of an indirect pathway in the basal ganglia through the δ opioid receptor." | 1.36 | Zonisamide: a new drug for Parkinson's disease. ( Murata, M, 2010) |
| "Zonisamide (ZNS) has proved effective for motor symptoms in PD and it may be also useful in the field of ICDs." | 1.36 | Zonisamide in managing impulse control disorders in Parkinson's disease. ( Anciones, B; Bermejo, PE; Ruiz-Huete, C, 2010) |
| "Generally, resting tremor of patients with Parkinson's disease is not the main therapeutic target in this disease." | 1.32 | [Effect of zonisamide on resting tremor resistant to antiparkinsonian medication]. ( Kohmoto, J; Kondo, T; Miwa, H; Nakanishi, I, 2003) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 14 (27.45) | 29.6817 |
| 2010's | 22 (43.14) | 24.3611 |
| 2020's | 15 (29.41) | 2.80 |
| Authors | Studies |
|---|---|
| Tsuboi, Y | 2 |
| Nakamura, M | 2 |
| Maruyama, H | 2 |
| Matsumoto, Y | 1 |
| Jing, XZ | 1 |
| Yuan, XZ | 1 |
| Luo, X | 1 |
| Zhang, SY | 1 |
| Wang, XP | 1 |
| Naito, T | 1 |
| Satake, W | 2 |
| Cha, PC | 2 |
| Kobayashi, K | 1 |
| Murata, M | 12 |
| Toda, T | 2 |
| Miyaue, N | 1 |
| Yabe, H | 1 |
| Kong, L | 1 |
| Xi, J | 1 |
| Jiang, Z | 1 |
| Yu, X | 1 |
| Liu, H | 1 |
| Wang, Z | 1 |
| Pillai, KS | 1 |
| Bhat, P | 1 |
| Srivastava, AK | 1 |
| Rajan, R | 1 |
| Radhakrishnan, DM | 1 |
| Elavarasi, A | 1 |
| Srivastava, MP | 1 |
| Singh, MB | 1 |
| Vishnu, VY | 1 |
| Prasad, K | 1 |
| Pandit, AK | 1 |
| Goyal, V | 1 |
| Yan, R | 3 |
| Cai, H | 3 |
| Cui, Y | 3 |
| Su, D | 3 |
| Cai, G | 3 |
| Lin, F | 3 |
| Feng, T | 3 |
| Mishima, T | 1 |
| Chiu, SW | 1 |
| Saiki, H | 1 |
| Yamaguchi, T | 1 |
| Shimo, Y | 1 |
| Maeda, T | 1 |
| Watanabe, H | 1 |
| Kashihara, K | 1 |
| Nomoto, M | 2 |
| Hattori, N | 2 |
| Deepthy, MS | 1 |
| Karun, KM | 1 |
| Harichandrakumar, KT | 1 |
| Nair, NS | 1 |
| Aboulatta, L | 1 |
| Haidar, L | 1 |
| Abou-Setta, A | 1 |
| Askin, N | 1 |
| Rabbani, R | 1 |
| Lavu, A | 1 |
| Peymani, P | 1 |
| Zarychanski, R | 1 |
| Eltonsy, S | 1 |
| Okamoto, T | 1 |
| Ando-Kanagawa, Y | 1 |
| Yamamoto, K | 1 |
| Gonzalez-Latapi, P | 1 |
| Bhowmick, SS | 1 |
| Saranza, G | 1 |
| Fox, SH | 1 |
| Suzuki, K | 1 |
| Fujita, H | 1 |
| Matsubara, T | 1 |
| Haruyama, Y | 1 |
| Kadowaki, T | 1 |
| Funakoshi, K | 1 |
| Watanabe, Y | 1 |
| Hirata, K | 1 |
| Abe, T | 1 |
| Goel, A | 1 |
| Sugumaran, R | 1 |
| Narayan, SK | 1 |
| Oki, M | 1 |
| Kaneko, S | 1 |
| Morise, S | 1 |
| Takenouchi, N | 1 |
| Hashizume, T | 2 |
| Tsuge, A | 1 |
| Wate, R | 1 |
| Kusaka, H | 1 |
| Uemura, MT | 1 |
| Asano, T | 1 |
| Hikawa, R | 1 |
| Yamakado, H | 1 |
| Takahashi, R | 1 |
| Kon, T | 1 |
| Ueno, T | 1 |
| Haga, R | 1 |
| Tomiyama, M | 1 |
| Mazumder, MK | 1 |
| Paul, R | 1 |
| Phukan, BC | 1 |
| Dutta, A | 1 |
| Chakrabarty, J | 1 |
| Bhattacharya, P | 1 |
| Borah, A | 1 |
| Ikeda, K | 1 |
| Yanagihashi, M | 1 |
| Miura, K | 1 |
| Ishikawa, Y | 1 |
| Hirayama, T | 1 |
| Takazawa, T | 1 |
| Kano, O | 1 |
| Kawabe, K | 1 |
| Mizumura, N | 1 |
| Iwasaki, Y | 1 |
| Ueno, SI | 1 |
| Saiki, S | 1 |
| Fujimaki, M | 1 |
| Takeshige-Amano, H | 1 |
| Hatano, T | 1 |
| Oyama, G | 1 |
| Ishikawa, KI | 1 |
| Yamaguchi, A | 1 |
| Nojiri, S | 1 |
| Akamatsu, W | 1 |
| Iwaki, H | 1 |
| Tagawa, M | 1 |
| Iwasaki, K | 1 |
| Kawakami, K | 1 |
| Tombini, M | 1 |
| Pellegrino, G | 1 |
| Di Pino, G | 1 |
| Assenza, G | 1 |
| Arawaka, S | 1 |
| Fukushima, S | 1 |
| Sato, H | 1 |
| Sasaki, A | 1 |
| Koga, K | 1 |
| Koyama, S | 1 |
| Kato, T | 1 |
| Tsujii, S | 1 |
| Ishisaka, M | 1 |
| Shimazawa, M | 1 |
| Hara, H | 1 |
| Hasegawa, K | 2 |
| Kanazawa, I | 3 |
| Fukasaka, J | 1 |
| Kochi, K | 1 |
| Shimazu, R | 1 |
| Matsunaga, S | 1 |
| Kishi, T | 1 |
| Iwata, N | 1 |
| Yano, R | 1 |
| Yokoyama, H | 1 |
| Kuroiwa, H | 1 |
| Kato, H | 1 |
| Araki, T | 1 |
| Yang, LP | 2 |
| Perry, CM | 2 |
| Janszky, J | 1 |
| Asanuma, M | 2 |
| Miyazaki, I | 2 |
| Diaz-Corrales, FJ | 2 |
| Kimoto, N | 1 |
| Kikkawa, Y | 1 |
| Takeshima, M | 1 |
| Miyoshi, K | 2 |
| Rösler, TW | 1 |
| Arias-Carrión, O | 1 |
| Höglinger, GU | 1 |
| Bermejo, PE | 2 |
| Ruiz-Huete, C | 1 |
| Anciones, B | 1 |
| Iijima, M | 1 |
| Osawa, M | 1 |
| Kobayashi, M | 1 |
| Uchiyama, S | 1 |
| Mochio, S | 1 |
| Sengoku, R | 1 |
| Kono, Y | 1 |
| Morita, M | 1 |
| Mitsumura, H | 1 |
| Takagi, S | 1 |
| Kamiyama, T | 1 |
| Oka, H | 1 |
| Ueda, Y | 1 |
| Tokashiki, S | 1 |
| Kanemaru, A | 1 |
| Kojima, T | 1 |
| Nakanishi, I | 1 |
| Kohmoto, J | 1 |
| Miwa, H | 2 |
| Kondo, T | 1 |
| Gluck, MR | 1 |
| Santana, LA | 1 |
| Granson, H | 1 |
| Yahr, MD | 1 |
| Zareba, G | 1 |
| Ogawa, N | 1 |
| Horiuchi, E | 1 |
14 reviews available for zonisamide and Parkinson Disease
| Article | Year |
|---|---|
An Update on Nondopaminergic Treatments for Motor and Non-motor Symptoms of Parkinson's Disease.
Topics: Antiparkinson Agents; Dopamine; Dyskinesias; Humans; Levodopa; Parkinson Disease; Serotonin; Zonisam | 2023 |
Zonisamide's Efficacy and Safety on Parkinson's Disease and Dementia with Lewy Bodies: A Meta-Analysis and Systematic Review.
Topics: Contusions; Humans; Lewy Body Disease; Parkinson Disease; Sleepiness; Zonisamide | 2022 |
Comparative efficacy and safety of monoamine oxidase type B inhibitors plus channel blockers and monoamine oxidase type B inhibitors as adjuvant therapy to levodopa in the treatment of Parkinson's disease: a network meta-analysis of randomized controlled
Topics: Antiparkinson Agents; Bayes Theorem; Humans; Indans; Levodopa; Monoamine Oxidase; Monoamine Oxidase | 2023 |
Comparative efficacy and safety of monoamine oxidase type B inhibitors plus channel blockers and monoamine oxidase type B inhibitors as adjuvant therapy to levodopa in the treatment of Parkinson's disease: a network meta-analysis of randomized controlled
Topics: Antiparkinson Agents; Bayes Theorem; Humans; Indans; Levodopa; Monoamine Oxidase; Monoamine Oxidase | 2023 |
Comparative efficacy and safety of monoamine oxidase type B inhibitors plus channel blockers and monoamine oxidase type B inhibitors as adjuvant therapy to levodopa in the treatment of Parkinson's disease: a network meta-analysis of randomized controlled
Topics: Antiparkinson Agents; Bayes Theorem; Humans; Indans; Levodopa; Monoamine Oxidase; Monoamine Oxidase | 2023 |
Comparative efficacy and safety of monoamine oxidase type B inhibitors plus channel blockers and monoamine oxidase type B inhibitors as adjuvant therapy to levodopa in the treatment of Parkinson's disease: a network meta-analysis of randomized controlled
Topics: Antiparkinson Agents; Bayes Theorem; Humans; Indans; Levodopa; Monoamine Oxidase; Monoamine Oxidase | 2023 |
Comparative efficacy and safety of monoamine oxidase type B inhibitors plus channel blockers and monoamine oxidase type B inhibitors as adjuvant therapy to levodopa in the treatment of Parkinson's disease: a network meta-analysis of randomized controlled
Topics: Antiparkinson Agents; Bayes Theorem; Humans; Indans; Levodopa; Monoamine Oxidase; Monoamine Oxidase | 2023 |
Comparative efficacy and safety of monoamine oxidase type B inhibitors plus channel blockers and monoamine oxidase type B inhibitors as adjuvant therapy to levodopa in the treatment of Parkinson's disease: a network meta-analysis of randomized controlled
Topics: Antiparkinson Agents; Bayes Theorem; Humans; Indans; Levodopa; Monoamine Oxidase; Monoamine Oxidase | 2023 |
Comparative efficacy and safety of monoamine oxidase type B inhibitors plus channel blockers and monoamine oxidase type B inhibitors as adjuvant therapy to levodopa in the treatment of Parkinson's disease: a network meta-analysis of randomized controlled
Topics: Antiparkinson Agents; Bayes Theorem; Humans; Indans; Levodopa; Monoamine Oxidase; Monoamine Oxidase | 2023 |
Comparative efficacy and safety of monoamine oxidase type B inhibitors plus channel blockers and monoamine oxidase type B inhibitors as adjuvant therapy to levodopa in the treatment of Parkinson's disease: a network meta-analysis of randomized controlled
Topics: Antiparkinson Agents; Bayes Theorem; Humans; Indans; Levodopa; Monoamine Oxidase; Monoamine Oxidase | 2023 |
Comparative efficacy and safety of monoamine oxidase type B inhibitors plus channel blockers and monoamine oxidase type B inhibitors as adjuvant therapy to levodopa in the treatment of Parkinson's disease: a network meta-analysis of randomized controlled
Topics: Antiparkinson Agents; Bayes Theorem; Humans; Indans; Levodopa; Monoamine Oxidase; Monoamine Oxidase | 2023 |
Efficacy and Safety of MAO-B Inhibitors Safinamide and Zonisamide in Parkinson's Disease: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
Topics: Adult; Dopamine Agents; Humans; Monoamine Oxidase; Parkinson Disease; Quality of Life; Randomized Co | 2023 |
Non-Dopaminergic Treatments for Motor Control in Parkinson's Disease: An Update.
Topics: Alanine; Animals; Antiparkinson Agents; Benzylamines; Drug Development; Drug Repositioning; Humans; | 2020 |
Zonisamide in Parkinson's disease: a current update.
Topics: Dopamine; Humans; Levodopa; Neurodegenerative Diseases; Parkinson Disease; Zonisamide | 2021 |
Combination Therapy with Zonisamide and Antiparkinson Drugs for Parkinson's Disease: A Meta-Analysis.
Topics: Antioxidants; Antiparkinson Agents; Drug Therapy, Combination; Humans; Isoxazoles; Parkinson Disease | 2017 |
[Therapy of Parkinson's disease--up to date].
Topics: Anticonvulsants; Antiparkinson Agents; Carbazoles; Dopamine Agents; Dopamine Agonists; Drug Design; | 2008 |
[Pharmacologic treatment of Parkinson disease].
Topics: Age of Onset; Antiparkinson Agents; Dopamine Agonists; Glutathione; Humans; Isoxazoles; Levodopa; Ne | 2009 |
[Role of zonisamid in treating epilepsy, Parkinson disorders and other neurological diseases].
Topics: Anticonvulsants; Bipolar Disorder; Calcium Channels, T-Type; Cholinergic Agents; Dopamine Agents; Dy | 2009 |
[The discovery of an antiparkinsonian drug, zonisamide].
Topics: Animals; Anticonvulsants; Dopamine; Humans; Isoxazoles; Male; Middle Aged; Parkinson Disease; Rats; | 2010 |
Novel therapeutic effects of the anti-convulsant, zonisamide, on Parkinson's disease.
Topics: Animals; Anticonvulsants; Antiparkinson Agents; Biogenic Monoamines; Calcium Channels, T-Type; Human | 2004 |
Zonisamide: review of its use in epilepsy therapy.
Topics: Animals; Anticonvulsants; Biological Availability; Child; Child, Preschool; Drug Interactions; Epile | 2005 |
Zonisamide for the treatment of Parkinson's disease.
Topics: Anticonvulsants; Antiparkinson Agents; Brain; Clinical Trials as Topic; Humans; Isoxazoles; Parkinso | 2007 |
8 trials available for zonisamide and Parkinson Disease
| Article | Year |
|---|---|
Zonisamide improves wearing off in Parkinson's disease without exacerbating dyskinesia: Post hoc analysis of phase 2 and phase 3 clinical trials.
Topics: Antiparkinson Agents; Double-Blind Method; Dyskinesias; Humans; Levodopa; Parkinson Disease; Zonisam | 2021 |
Polysomnographic and Clinical Parameters before and after Zonisamide Therapy for Parkinson's Disease.
Topics: Humans; Parkinson Disease; Polysomnography; Quality of Life; Sleep; Sleep Wake Disorders; Zonisamide | 2023 |
Zonisamide add-on in tremor-dominant Parkinson's disease- A randomized controlled clinical trial.
Topics: Double-Blind Method; Essential Tremor; Humans; Parkinson Disease; Treatment Outcome; Tremor; Zonisam | 2022 |
Zonisamide effects on sleep problems and depressive symptoms in Parkinson's disease.
Topics: Depression; Humans; Parkinson Disease; Sleep Wake Disorders; Tremor; Zonisamide | 2021 |
Zonisamide improves wearing-off in Parkinson's disease: A randomized, double-blind study.
Topics: Aged; Anticonvulsants; Dopamine Agents; Double-Blind Method; Drug Therapy, Combination; Female; Huma | 2015 |
Zonisamide improves motor function in Parkinson disease: a randomized, double-blind study.
Topics: Adult; Aged; Aged, 80 and over; Dose-Response Relationship, Drug; Double-Blind Method; Female; Human | 2007 |
Zonisamide in patients with essential tremor and Parkinson's disease.
Topics: Anticonvulsants; Essential Tremor; Humans; Isoxazoles; Parkinson Disease; Zonisamide | 2007 |
Zonisamide has beneficial effects on Parkinson's disease patients.
Topics: Aged; Animals; Anticonvulsants; Antiparkinson Agents; Corpus Striatum; Dopamine; Dopamine Agonists; | 2001 |
29 other studies available for zonisamide and Parkinson Disease
| Article | Year |
|---|---|
Comparative whole transcriptome analysis of Parkinson's disease focusing on the efficacy of zonisamide.
Topics: Antiparkinson Agents; Gene Expression Profiling; Humans; Parkinson Disease; Transcriptome; Zonisamid | 2022 |
Risk factors for developing dyskinesia among Parkinson's disease patients with wearing-off: J-FIRST.
Topics: Antiparkinson Agents; Catechol O-Methyltransferase; Dopamine Agonists; Dyskinesias; Female; Humans; | 2023 |
Investigation of the Utility of Multivariate Meta-Analysis Methods in Estimating the Summary Dose Response Curve.
Topics: Humans; Meta-Analysis as Topic; Parkinson Disease; Research Design; Zonisamide | 2022 |
[Parkinson's Disease: amantadine, zonisamide, dabrafenib].
Topics: Amantadine; Antiparkinson Agents; Drug Repositioning; Genome-Wide Association Study; Humans; Imidazo | 2019 |
Genome-wide association study identifies zonisamide responsive gene in Parkinson's disease patients.
Topics: Aged; Antiparkinson Agents; Asian People; Cell Cycle Proteins; DNA-Binding Proteins; Female; Genome- | 2020 |
[Effects of switching from dopamine agonists to zonisamide on psychiatric and motor symptoms in patients with Parkinson's disease].
Topics: Dopamine Agonists; Drug Substitution; Hallucinations; Humans; Levodopa; Parkinson Disease; Zonisamid | 2021 |
Zonisamide ameliorates levodopa-induced dyskinesia and reduces expression of striatal genes in Parkinson model rats.
Topics: Animals; Anticonvulsants; Corpus Striatum; Dopamine Agents; Dyskinesia, Drug-Induced; Female; Gene E | 2017 |
Zonisamide inhibits monoamine oxidase and enhances motor performance and social activity.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Antiparkinson Agents; Astrocytes; Brain; Dopamine; Explorat | 2017 |
The factors associated with impulse control behaviors in Parkinson's disease: A 2-year longitudinal retrospective cohort study.
Topics: Adenosine A2 Receptor Antagonists; Age Factors; Aged; Antiparkinson Agents; Calcium Channel Blockers | 2018 |
Garcinol, an effective monoamine oxidase-B inhibitor for the treatment of Parkinson's disease.
Topics: Humans; Inflammation; Isoxazoles; Levodopa; Ligands; Molecular Conformation; Molecular Docking Simul | 2018 |
Zonisamide cotreatment delays striatal dopamine transporter reduction in Parkinson disease: A retrospective, observational cohort study.
Topics: Aged; Antiparkinson Agents; Corpus Striatum; Disease Progression; Dopamine Plasma Membrane Transport | 2018 |
Zonisamide Administration Improves Fatty Acid β-Oxidation in Parkinson's Disease.
Topics: Aged; Aged, 80 and over; Antiparkinson Agents; Carnitine; Fatty Acids; Female; Humans; Levodopa; Mal | 2018 |
Comparison of zonisamide with non-levodopa, anti-Parkinson's disease drugs in the incidence of Parkinson's disease-relevant symptoms.
Topics: Aged; Aged, 80 and over; Antiparkinson Agents; Female; Humans; Levodopa; Male; Middle Aged; Parkinso | 2019 |
Zonisamide for seizures in Parkinson's disease with dementia.
Topics: Aged; Anticonvulsants; Dementia; Humans; Isoxazoles; Male; Parkinson Disease; Seizures; Zonisamide | 2013 |
Zonisamide attenuates α-synuclein neurotoxicity by an aggregation-independent mechanism in a rat model of familial Parkinson's disease.
Topics: alpha-Synuclein; Animals; Cell Count; Dependovirus; Disease Models, Animal; Dopaminergic Neurons; Is | 2014 |
Zonisamide suppresses endoplasmic reticulum stress-induced neuronal cell damage in vitro and in vivo.
Topics: Animals; Anticonvulsants; Antiparkinson Agents; Cell Death; Cell Line, Tumor; Cell Survival; Disease | 2015 |
A novel anti-Parkinsonian agent, zonisamide, attenuates MPTP-induced neurotoxicity in mice.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Anticonvulsants; Antiparkinson Agents; Astroc | 2009 |
Zonisamide: in Parkinson's disease.
Topics: Animals; Antioxidants; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Administration | 2009 |
Zonisamide in Parkinson's disease: profile report.
Topics: Antioxidants; Humans; Isoxazoles; Parkinson Disease; Treatment Outcome; Zonisamide | 2010 |
Neuroprotective effects of zonisamide target astrocyte.
Topics: Animals; Antiparkinson Agents; Astrocytes; Basal Ganglia; Carbidopa; Cells, Cultured; Disease Models | 2010 |
Zonisamide: aspects in neuroprotection.
Topics: Animals; Anticonvulsants; Antiparkinson Agents; Humans; Isoxazoles; Neurons; Neuroprotective Agents; | 2010 |
Zonisamide: a new drug for Parkinson's disease.
Topics: Animals; Anticonvulsants; Antiparkinson Agents; Clinical Trials as Topic; Half-Life; Humans; Isoxazo | 2010 |
Zonisamide in managing impulse control disorders in Parkinson's disease.
Topics: Aged; Antioxidants; Disruptive, Impulse Control, and Conduct Disorders; Female; Humans; Isoxazoles; | 2010 |
Efficacy of zonisamide in a case of Parkinson's disease with intractable resting and re-emergent tremor.
Topics: Aged; Antiparkinson Agents; Electromyography; Female; Humans; Isoxazoles; Parkinson Disease; Rest; S | 2011 |
Actigraphic study of tremor before and after treatment with zonisamide in patients with Parkinson's disease.
Topics: Actigraphy; Anticonvulsants; Humans; Isoxazoles; Motor Activity; Parkinson Disease; Treatment Outcom | 2012 |
Effect of zonisamide co-administration with levodopa on global gene expression in the striata of rats with Parkinson's disease.
Topics: Animals; Anticonvulsants; Antiparkinson Agents; Corpus Striatum; Disease Models, Animal; Drug Therap | 2012 |
[Effect of zonisamide on resting tremor resistant to antiparkinsonian medication].
Topics: Aged; Aged, 80 and over; Anticonvulsants; Antiparkinson Agents; Humans; Isoxazoles; Levodopa; Male; | 2003 |
Novel dopamine releasing response of an anti-convulsant agent with possible anti-Parkinson's activity.
Topics: 3,4-Dihydroxyphenylacetic Acid; Adrenergic Agents; Animals; Antiparkinson Agents; Behavior, Animal; | 2004 |
Preventing effects of a novel anti-parkinsonian agent zonisamide on dopamine quinone formation.
Topics: alpha-Synuclein; Animals; Antioxidants; Biopterins; Cell-Free System; Cells, Cultured; Cytosol; Dopa | 2008 |